Related Experiment Video
Updated: Feb 15, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Mathieu Kerneis1, Usama Talib1, Tarek Nafee1
1PERFUSE Study Group, Cardiovascular Division, Departments of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Insights
For patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), non-vitamin K oral anticoagulant (NOAC)-based triple therapy significantly reduces bleeding risk compared to traditional warfarin regimens.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Dual antiplatelet therapy (DAPT) is standard after percutaneous coronary intervention (PCI).
- Atrial fibrillation (AF) patients undergoing PCI often require oral anticoagulants (OACs) alongside DAPT.
- Traditional triple therapy (OAC + DAPT) significantly increases bleeding risk.
Purpose of the Study:
- To review the rationale and evidence for triple antithrombotic therapy in AF patients post-PCI.
- To evaluate non-vitamin K OAC (NOAC)-based strategies versus warfarin-based regimens.
Main Methods:
- Review of randomized trials, including PIONEER AF-PCI and REDUAL PCI.
- Comparison of NOAC-based triple therapy with vitamin K antagonist (VKA)-based triple therapy.
Main Results:
- NOAC-based strategies demonstrated superior safety profiles.
- Reduced bleeding risk observed with NOAC-based triple therapy compared to VKA-based therapy.
Conclusions:
- NOAC-based triple antithrombotic therapy is a safer alternative for AF patients undergoing PCI.
- These findings support a shift from traditional VKA-based triple therapy.
Abstract:
Dual antiplatelet therapy (DAPT) has been the cornerstone of antithrombotic management for patients undergoing percutaneous coronary intervention (PCI). However, approximately 10% of these patients have concomitant atrial fibrillation (AF) and require chronic oral anticoagulant (OAC) in addition to DAPT. This traditional "triple therapy" has been associated with a three to four-fold increased risk of bleeding. The safety of non-vitamin K OAC (NOAC)-based strategies, using a NOAC plus a P2Y12 inhibitor, has been compared to vitamin K antagonist (VKA)-based triple therapy in the PIONEER AF-PCI and REDUAL PCI randomized trials, both of which have demonstrated that NOAC-based strategies are safer and provide an attractive alternative to VKA-based triple therapy among AF patients who undergo PCI. This article reviews the rationale, evidence, and recent evaluation of triple antithrombotic therapy among AF patients undergoing PCI.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Nursing Interventions I: Taxonomy of Nursing Interventions
A nursing intervention is a treatment or action based on scientific concepts and knowledge from the nursing, behavioral, and physical sciences. Identifying and prioritizing nursing interventions based on the desired outcome...
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Nursing Interventions II: Selecting and Classifying the Nursing Interventions
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....

